During the final stage of the research, the developed analytical method was performed in a fully automated manner. Graphical abstract.BACKGROUND Polyacrylamide hydrogel (PAAG) was once used as an important injection for breast augmentation though it has been banned in China for more than 10 years. Secondary breast deformity after removing PAAG poses a challenging problem. The aim of this article is to introduce types of breast deformity induced by two types of PAAG based on MRI examination and corresponding treatment strategies. METHODS From 2008 to 2017, 300 patients with the history of injectable PAAG were reviewed. From their medical history, two types of PAAG injections were imported Interfall and domestic Amazingel, 182 patients received Interfall injection and 118 patients received Amazingel injection. MRI was used as a regular examination preoperatively. According to MRI examinations, breast deformities were classified into nodular type, flow type and mixed type. RESULTS All of them underwent PAAG removal operations. In the 182 patients with Interfall injection There were only 5 cases of nodular type, 3 cases received immediate breas, and none of cases received immediate breast augmentation . CONCLUSIONS Breast deformity induced by two types of PAAG can be classified into three types based on MRI examinations, which is very critical for preoperative evaluation and classification. Each type of deformity has its own characteristics, which serves as a guide for whether a first-stage or a second-stage prosthesis implant can be implemented. The proportion of patients who can have breast augmentation in the first or second phase after injection of Interfall is significantly higher than that of patients who have injections of Amazingel. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.The objective of our study was to determine the prevalence, risk factors, and the impact of obstructive sleep apnea (OSA) in the adult with congenital heart disease (ACHD). One hundred forty-nine consecutive patients seen in our ACHD program were screened for OSA using the Berlin Questionnaire. Demographic and clinical details on subjects were collected through a chart review. Clinical variables were analyzed to determine risk factors for positive OSA screen, as well as associated outcomes. Seventy-seven (52%) of our cohort were females. The median age of the cohort was 33 years (range = 18-74) and median weight was 79 kg (range = 50-145 kg). Overall, 47 (31%) of our cohort were found to have a positive OSA screen using the Berlin questionnaire. Median age of the patients whom tested positive was 34 years. Compared to patients with a negative screen, patients with a positive OSA screen were more likely to be heavier with a median weight of 99 kg vs 71 kg (p  30) compared to 15% in the negative group (p  less then  0.02). Patients with a positive screen were more likely to have other co-morbidities including diabetes (p  less then  0.04), hypertension (p  less then  0.05), depression (p  less then  0.002), and were more likely to have decreased exercise capacity (p  less then  0.01) and a defibrillator (p  less then  0.007). Our data demonstrates that OSA is common in the ACHD patient and is associated with increasing weight and BMI. Patients with a positive screen are at increased risk for multiple co morbidities including diabetes, hypertension, and depression. We believe our data supports the use of screening protocols for OSA in the ACHD population in effort to identify early, treat, and potentially prevent late complications.Melatonin, as a neuroendocrine hormone, is produced primarily by the pineal gland. Melatonin, a pleotropic molecule, acts as a free radical scavenger, antioxidant, and regulator of circadian rhythm in mammals via several receptor-mediated and non-receptor-mediated mechanisms. This inexpensive, well-tolerated, and multi-target molecule has a great therapeutic potential against many diseases. Many evidences have proposed that melatonin plays a key role in the pathophysiology of various cardiovascular diseases. The aim of this paper is to discuss the data and experiments regarding the effects of melatonin in management of cardiovascular risk factors. PubMed, EMBASE, and Scopus have been searched for data collection using related keywords. Two hundred ten articles were included in this review from 2253 founded documents. Using these documents, the main mechanisms of action of melatonin are discussed and summarized in this article. https://www.selleckchem.com/products/azd9291.html Also, recent progresses regarding melatonin's effects on cardiovascular risk factors and diseases including diabetes, hypertension, hyperlipidemia, obesity, myocardial ischemia-reperfusion injury, pulmonary hypertension, and atherosclerosis have been reviewed. Many studies have demonstrated the beneficial effects of melatonin in prevention and improving cardiovascular risk factors, and this inexpensive and well-tolerated drug can be strongly proposed in different cardiovascular diseases as well as metabolic syndrome.The aim of the present study was to assess the effect of diethylcarbamazine (DEC), siver nanoparticles (AgNPs), nitazoxanide (NTZ), and a combination of nitazoxanide with silver nanoparticle (NTZ+AgNPs) against the microfilariae of Setaria cervi in experimentally infected albino rats. The NTZ+AgNPs was synthesized and subsequently characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), UV-visible absorption Spectra (UV-VIS), Fourier transforms infrared spectroscopy (FTIR), and energy dispersive X-ray (EDX) spectra. Twenty male albino rats were divided into 5 groups. Groups I, II, III, and IV were treated with DEC, AgNPs, NTZ, and NTZ+AgNPs, while group V was taken as untreated infected control. After the establishment of infection, microfilaraemic rats were treated with aforesaid drugs for 6 days at 100 mg/kg body weight. Efficacy of drugs was observed by counting the microfilariae in the blood of albino rats every 3rd day till microfilariae disappeared. Blood was taken at every 10 days interval till 40 days for biochemical studies to assess the level of antioxidant enzymes.